The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biodyn Regulatory News (OBD)

Share Price Information for Oxford Biodyn (OBD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.80
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.18 (2.308%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 7.80
OBD Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

3 Oct 2023 16:37

RNS Number : 5742O
Oxford BioDynamics PLC
03 October 2023
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BD5H8572

Issuer Name

Oxford BioDynamics Plc

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

SENECA PARTNERS LIMITED

City of registered office (if applicable)

 

Country of registered office (if applicable)

UK

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

PLATFORM SECURITIES NOMINEES LIMITED

WOODSIDE NOMINEES LIMITED

City of registered office (if applicable)

LONDON

Country of registered office (if applicable)

UK

5. Date on which the threshold was crossed or reached

02-OCT-2023

6. Date on which Issuer notified

03-OCT-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.930000

0.000000

4.930000

9,978,822

Position of previous notification (if applicable)

5.720000

0.000000

5.720000

11,578,822

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BD5H8572   

9,978,822

4.930000

Sub Total 8.A

9,978,822

4.930000

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

03-OCT-2023

13. Place Of Completion

Haydock UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEASEDEDKDFFA
Date   Source Headline
15th Mar 202311:43 amRNSAIM Rule 17 Schedule 2(g) Update
3rd Mar 20234:33 pmRNSPublication of FY22 Annual Report
23rd Feb 202310:36 amRNSPDMR Dealing
6th Feb 20237:00 amRNSOBD Prostate Screening EpiSwitch Blood Test Update
27th Jan 20232:36 pmRNSDirector/PDMR Shareholding
24th Jan 20237:00 amRNSPreliminary Results and Notice of AGM
21st Dec 20227:00 amRNSNotice of FY22 Results and Investor Webinar
19th Dec 20227:00 amRNSOBD in San Francisco for JPM Healthcare conf 2023
16th Dec 20227:00 amRNSInitial assessment of EpiSwitch assay in ALS trial
14th Dec 202212:35 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSExercise period extension - existing share options
1st Dec 20222:14 pmRNSHolding(s) in Company
28th Nov 20227:00 amRNSHolding(s) in Company
21st Nov 20227:00 amRNSDiscussion about EpiSwitch CiRT at Key Summit
18th Nov 20224:40 pmRNSSecond Price Monitoring Extn
18th Nov 20224:35 pmRNSPrice Monitoring Extension
14th Nov 202211:10 amRNSDirector/PDMR Shareholding
9th Nov 20224:07 pmRNSDirector/PDMR Shareholding
8th Nov 20221:57 pmRNSHolding(s) in Company
2nd Nov 202212:37 pmRNSHolding(s) in Company
2nd Nov 202212:35 pmRNSHolding(s) in Company
2nd Nov 202212:33 pmRNSHolding(s) in Company
1st Nov 20221:20 pmRNSTotal Voting Rights
1st Nov 202212:39 pmRNSTotal Voting Rights
1st Nov 202210:57 amRNSHolding(s) in Company
31st Oct 202211:05 amRNSHolding(s) in Company
31st Oct 202211:04 amRNSHolding(s) in Company
31st Oct 202211:02 amRNSHolding(s) in Company
31st Oct 202210:58 amRNSHolding(s) in Company
31st Oct 202210:57 amRNSHolding(s) in Company
31st Oct 202210:56 amRNSHolding(s) in Company
28th Oct 20222:36 pmRNSHolding(s) in Company
27th Oct 202212:09 pmRNSResult of General Meeting, Director/PDMR Dealings
25th Oct 20222:30 pmRNSResult of Open Offer
7th Oct 202212:00 pmRNSProposed Placing and Open Offer
3rd Oct 20227:00 amRNSUS Reimbursement Code for CiRT now available
15th Sep 20227:00 amRNSESMO data highlights unique benefit of EpiSwitch
6th Sep 20227:00 amRNSCiRT highlighted at ESMO 2022 presentation
5th Jul 20227:00 amRNSUS reimbursement code for EpiSwitch® CiRT
1st Jul 20224:13 pmRNSDirector/PDMR Shareholding
28th Jun 20227:00 amRNSHalf-year Report
21st Jun 20227:00 amRNSEpiSwitch® CiRT now available in the UK
17th Jun 20227:00 amRNSNotice of Interim Results Webinar
15th Jun 20227:00 amRNSNotice of Results
14th Jun 20227:00 amRNSOBD EpiSwitch® CiRT well received at ASCO 2022
20th May 20223:50 pmRNSDirector/PDMR Shareholding
20th May 20227:00 amRNSPDMR Dealing / Grant of Share Options
13th May 20223:57 pmRNSPDMR Dealing / Grant of Share Options
5th May 20227:00 amRNSOBD to present CiRT clinical utility data at ASCO
28th Apr 202210:54 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.